The roles of abnormal renal sodium handling in hypertension associated with metabolic syndrome

Current Hypertension Reviews

Volumn 4, Issue 3, 2008, Pages 197-202

  Seki, George ^a   Yamada, Hideomi ^a   Li, Yuehong ^a,b   Horita, Shoko ^a   Suzuki, Masashi ^a   Fujita, Toshiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Angiotensin II; Insulin; IRS; Norepinephrine; Renal proximal tubules

Indexed keywords

11,12 EPOXY 5,8,14 ICOSATRIENOIC ACID; 2 MORPHOLINO 8 PHENYLCHROMONE; 5,6 EPOXY 8,11,14 ICOSATRIENOIC ACID; ACETYLCYSTEINE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; BICARBONATE SODIUM COTRANSPORTER; CAPTOPRIL; CYTOCHROME P450; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; LEPTIN; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; PD 12319; RAMIPRIL; SODIUM; TELMISARTAN; UNCLASSIFIED DRUG; VALSARTAN; WORTMANNIN;

ADRENERGIC SYSTEM; BLOOD PRESSURE REGULATION; DRUG ACTIVITY; ENZYME ACTIVITY; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY PROXIMAL TUBULE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW; SODIUM RETENTION; SODIUM TRANSPORT; SODIUM URINE LEVEL; SYMPATHETIC NERVE;

EID: 54749151856     PISSN: 15734021     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340208785132653     Document Type: Review

References (92)

1. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716.
2. Cooper-DeHoff RM, Pepine CJ. Metabolic syndrome and cardiovascular disease: challenges and opportunities. Clin Cardiol 2007; 30; 593-597.
3. Cheung BM, Ong KL, Man YB, Wong LY, Lau CP, Lam KS. Prevalence of the metabolic syndrome in the United States National Health and Nutrition Examination Survey 1999-2002 according to different defining criteria. J Clin Hypertens (Greenwich) 2006; 8: 562-570.
4. Garrison RJ, Kannel WB, Stokes J, 3rd, Castelli WP. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 1987; 16: 235-251.
5. Hall JE, Hildebrandt DA, Kuo J. Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens 2001; 14: 103S-115S.
6. Grundy SM, Brewer HB, Jr., Cleeman JI, Smith SC, Jr., Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438.
7. El-Atat FA, Stas SN, McFarlane SI, Sowers JR. The relationship between hyperinsulinemia, hypertension and progressive renal disease. J Am Soc Nephrol 2004; 15: 2816-2827.
8. Barbato A, Cappuccio FP, Folkerd EJ, et al. Metabolic syndrome and renal sodium handling in three ethnic groups living in England. Diabetologia 2004; 47: 40-46.
9. Strazzullo P, Barbato A, Galletti F, et al. Abnormalities of renal sodium handling in the metabolic syndrome. Results of the Olivetti Heart Study. J Hypertens 2006; 24: 1633-1639.
10. Pessin JE, Saltiel AR. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 2000; 106: 165-169.
11. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414: 799-806.
12. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
13. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
14. Velloso LA, Folli F, Perego L, Saad MJ. The multi-faceted crosstalk between the insulin and angiotensin II signaling systems. Diabetes Metab Res Rev 2006; 22: 98-107.
15. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001; 86: 713-718.
16. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004; 286: H1597-H1602.
17. Banday AA, Siddiqui AH, Menezes MM, Hussain T. Insulin treatment enhances AT1 receptor function in OK cells. Am J Physiol Renal Physiol 2005; 288: F1213-F1219.
18. Hall JE, Crook ED, Jones DW, Wofford MR, Dubbert PM. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 2002; 324: 127-137.
19. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.
20. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
21. Kjeldsen SE, Julius S, Mancia G, et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens 2006; 24: 1405-1412.
22. Shiuchi T, Iwai M, Li HS, et al. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 2004; 43: 1003-1010.
23. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/ angiotensin II crosstalk. J Clin Invest 1997; 100: 2158-2169.
24. Wei Y, Whaley-Connell AT, Chen K, et al. NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat. Hypertension 2007; 50: 384-391.
25. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109: 2054-2057.
26. Schupp M, Clemenz M, Gineste R, et al. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 2005; 54: 3442-3452.
27. Harris PJ, Young JA. Dose-dependent stimulation and inhibition of proximal tubular sodium reabsorption by angiotensin II in the rat kidney. Pflugers Arch 1977; 367: 295-297.
28. Schuster VL, Kokko JP, Jacobson HR. Angiotensin II directly stimulates sodium transport in rabbit proximal convoluted tubules. J Clin Invest 1984; 73: 507-515.
29. Alper SL. Molecular physiology of SLC4 anion exchangers. Exp Physiol 2006; 91: 153-161.
30. Han HJ, Park SH, Koh HJ, Taub M. Mechanism of regulation of Na transport by angiotensin II in primary renal cells. Kidney Int 2000; 57: 2457-2467.
31. 3 cotransport and K conductance in renal proximal tubules. I. Effect of picomolar concentrations. Pflugers Arch 1994; 427: 143-150.
32. 3 cotransport and K conductance in renal proximal tubules. II. Effect of micromolar concentrations. Pflugers Arch 1994; 427: 151-156.
33. Houillier P, Chambrey R, Achard JM, Froissart M, Poggioli J, Paillard M. Signaling pathways in the biphasic effect of angiotensin II on apical Na/ H antiport activity in proximal tubule. Kidney Int 1996; 50: 1496-1505.
34. +-ATPase: a final common pathway for regulation of natriuresis. FASEB J 1994; 8: 436-439.
35. Liu FY, Cogan MG. Angiotensin II stimulates early proximal bicarbonate absorption in the rat by decreasing cyclic adenosine monophosphate. J Clin Invest 1989; 84: 83-91.
36. 3 cotransporter: IV. Mechanisms of the stimulatory effect of angiotensin II. J Am Soc Nephrol 1995; 6: 1202-1208.
37. Poggioli J, Lazar G, Houillier P, Gardin JP, Achard JM, Paillard M. Effects of angiotensin II and nonpeptide receptor antagonists on transduction pathways in rat proximal tubule. Am J Physiol 1992; 263: C750-C758.
38. Dulin NO, Alexander LD, Harwalkar S, Falck JR, Douglas JG. Phospholipase A2-mediated activation of mitogen-activated protein kinase by angiotensin II. Proc Natl Acad Sci USA 1998; 95: 8098-8102.
39. Haithcock D, Jiao H, Cui XL, Hopfer U, Douglas JG. Renal proximal tubular AT2 receptor: signaling and transport. J Am Soc Nephrol 1999; 10 Suppl 11: S69-S74.
40. Igarashi T, Inatomi J, Sekine T, et al. Mutations in SLC4A4 cause permanent isolated proximal renal tubular acidosis with ocular abnormalities. Nat Genet 1999; 23: 264-266.
41. - cotransporter by angiotensin II type 1A receptor. Hypertension 2002; 40: 707-712.
42. 1A receptor. J Am Soc Nephrol 2003; 14: 1116-1122.
43. --ATPase activity via a NO/ cGMP-dependent pathway. Am J Physiol Renal Physiol 2006; 290: F1430-F1436.
44. Grone HJ, Simon M, Fuchs E. Autoradiographic characterization of angiotensin receptor subtypes in fetal and adult human kidney. Am J Physiol 1992; 262: F326-F331.
45. Allen AM, Zhuo J, Mendelsohn FA. Localization of angiotensin AT1 and AT2 receptors. J Am Soc Nephrol 1999; 10 Suppl 11: S23-S29.
46. - transport. J Am Soc Nephrol 2008; 19: 252-259.
47. Romero MF, Madhun ZT, Hopfer U, Douglas JG. An epoxygenase metabolite of arachidonic acid 5,6 epoxy-cicosatrienoic acid mediates angiotensin-induced natriuresis in proximal tubular epithelium. Adv Prostaglandin Thromboxane Leukot Res 1991; 21A: 205-208.
48. Navar LG, Harrison-Bernard LM, Wang CT, Cervenka L, Mitchell KD. Concentrations and actions of intraluminal angiotensin II. J Am Soc Nephrol 1999; 10 Suppl 11: S189-S195.
49. Thomson SC, Deng A, Wead L, Richter K, Blantz RC, Vallon V. An unexpected role for angiotensin II in the link between dietary salt and proximal reabsorption. J Clin Invest 2006; 116: 1110-1116.
50. Imig JD. Eicosanoids and renal vascular function in diseases. Clin Sci (Lond) 2006; 111: 21-34.
51. Wang MH, Smith A, Zhou Y, et al. Downregulation of renal CYP-derived eicosanoid synthesis in rats with diet-induced hypertension. Hypertension 2003; 42: 594-599.
52. Dey A, Maric C, Kaesemeyer WH, et al. Rofecoxib decreases renal injury in obese Zucker rats. Clin Sci (Lond) 2004; 107: 561-570.
53. Dey A, Williams RS, Pollock DM, Stepp DW, Newman JW, Hammock BD, et al. Altered kidney CYP2C and cyclooxygenase-2 levels are associated with obesity-related albuminuria. Obes Res 2004; 12: 1278-1289.
54. Zhao X, Dey A, Romanko OP, et al. Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 2005; 288: R188-R196.
55. Wei Y, Lin DH, Kemp R, et al. Arachidonic acid inhibits epithelial Na channel via cytochrome P450 (CYP) epoxygenase-dependent metabolic pathways. J Gen Physiol 2004; 124: 719-727.
56. Nakagawa K, Holla VR, Wei Y, et al. Salt-sensitive hypertension is associated with dysfunctional Cyp4a10 gene and kidney epithelial sodium channel. J Clin Invest 2006; 116: 1696-1702.
57. Esler M. The sympathetic system and hypertension. Am J Hypertens 2000; 13: 99S-105S.
58. Kassab S, Kato T, Wilkins FC, Chen R, Hall JE, Granger JP. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 1995; 25: 893-897.
59. Bell-Reuss E, Trevino DL, Gottschalk CW. Effect of renal sympathetic nerve stimulation on proximal water and sodium reabsorption. J Clin Invest 1976; 57: 1104-1107.
60. Chan YL. The role of norepinephrine in the regulation of fluid absorption in the rat proximal tubule. J Pharmacol Exp Ther 1980; 215: 65-70.
61. +-ATPase and solute transport in rabbit proximal tubules. Am J Physiol 1987; 252: F215-F220.
62. 3-absorption to norepinephrine. Pflugers Arch 2000; 440: 908-917.
63. + conductance. Pflugers Arch 1997; 434: 373-382.
64. - in isolated rabbit renal proximal tubule. Pflugers Arch 1993; 425: 409-416.
65. Seki G, Coppola S, Yoshitomi K, et al. On the mechanism of bicarbonate exit from renal proximal tubular cells. Kidney Int 1996; 49: 1671-1677.
66. 3 cotransport stoichiometry and of response to acetazolamide. Pflugers Arch 1997; 434: 383-391.
67. - cotransporter in rabbits and normotensive rats but not in spontaneously hypertensive rats. Kidney Int 2000; 57: 534-543.
68. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149: 1514-1520.
69. Zavaroni I, Bonora E, Pagliara M, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 1989; 320: 702-706.
70. DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest 1975; 55: 845-855.
71. Natali A, Quinones Galvan A, Santoro D, et al. Relationship between insulin release, antinatriuresis and hypokalaemia after glucose ingestion in normal and hypertensive man. Clin Sci (Lond) 1993; 85: 327-335.
72. Quinones-Galvan A, Ferrannini E. Renal effects of insulin in man. J Nephrol 1997; 10: 188-191.
73. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97: 2601-2610.
74. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37: 1053-1059.
75. Hall JE. Hyperinsulinemia: a link between obesity and hypertension? Kidney Int 1993; 43: 1402-1417.
76. Hall JE, Brands MW, Kivlighn SD, Mizelle HL, Hildebrandt DA, Gaillard CA. Chronic hyperinsulinemia and blood pressure. Interaction with catecholamines? Hypertension 1990; 15: 519-527.
77. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 1991; 87: 2246-2252.
78. Brands MW, Hildebrandt DA, Mizelle HL, Hall JE. Hypertension during chronic hyperinsulinemia in rats is not salt-sensitive. Hypertension 1992; 19: I83-89.
79. Tiwari S, Riazi S, Ecelbarger CA. Insulin's impact on renal sodium transport and blood pressure in health, obesity, and diabetes. Am J Physiol Renal Physiol 2007; 293: F974-F984.
80. Butlen D, Vadrot S, Roseau S, Morel F. Insulin receptors along the rat nephron: [125I] insulin binding in microdissected glomeruli and tubules. Pflugers Arch 1988; 412: 604-612.
81. Baum M. Insulin stimulates volume absorption in the rabbit proximal convoluted tubule. J Clin Invest 1987; 79: 1104-1109.
82. Tamemoto H, Kadowaki T, Tobe K, et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 1994; 372: 182-186.
83. Araki E, Lipes MA, Patti ME, et al. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 1994; 372: 186-190.
84. Kubota T, Kubota N, Moroi M, et al. Lack of insulin receptor substrate-2 causes progressive neointima formation in response to vessel injury. Circulation 2003; 107: 3073-3080.
85. Yamauchi T, Tobe K, Tamemoto H, et al. Insulin signalling and insulin actions in the muscles and livers of insulin-resistant, insulin receptor substrate 1-deficient mice. Mol Cell Biol 1996; 16: 3074-3084.
86. Previs SF, Withers DJ, Ren JM, White MF, Shulman GI. Contrasting effects of IRS-1 versus IRS-2 gene disruption on carbohydrate and lipid metabolism in vivo. J Biol Chem 2000; 275: 38990-38994.
87. Sesti G, Federici M, Hribal ML, Lauro D, Sbraccia P, Lauro R. Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J 2001; 15: 2099-2111.
88. Nandi A, Kitamura Y, Kahn CR, Accili D. Mouse models of insulin resistance. Physiol Rev 2004; 84: 623-647.
89. Zheng Y, Yamada H, Sakamoto K, et al. Roles of insulin receptor substrates in insulin-induced stimulation of renal proximal bicarbonate absorption. J Am Soc Nephrol 2005; 16: 2288-2295.
90. Goodyear LJ, Giorgino F, Sherman LA, Carey J, Smith RJ, Dohm GL. Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. J Clin Invest 1995; 95: 2195-2204.
91. Rondinone CM, Wang LM, Lonnroth P, Wesslau C, Pierce JH, Smith U. Insulin receptor substrate (IRS) 1 is reduced and IRS-2 is the main docking protein for phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 1997; 94: 4171-4175.
92. Carvalho E, Jansson PA, Axelsen M, et al. Low cellular IRS 1 gene and protein expression predict insulin resistance and NIDDM. FASEB J 1999; 13: 2173-2178.